Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchAzithromycinAzithromycin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19

Omrani et al., eClinicalMedicine, doi:10.1016/j.eclinm.2020.100645, Q-PROTECT
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization -33% Improvement Relative Risk Progression to pneumonia 67% Symptomatic at day 21 -100% Improvement in Ct -4% Azithromycin  Q-PROTECT  EARLY TREATMENT  DB RCT Is early treatment with azithromycin beneficial for COVID-19? Double-blind RCT 304 patients in Qatar (April - August 2020) Worse recovery with azithromycin (not stat. sig., p=0.5) c19early.org Omrani et al., eClinicalMedicine, November 2020 Favorsazithromycin Favorscontrol 0 0.5 1 1.5 2+
Low risk patient RCT for HCQ+AZ and HCQ vs. control, not showing any significant differences.
Authors note that the results are not applicable to higher risk patients, that positive PCR may simply reflect detection of inactive (non-infectious) viral remnants, that an alternative dosage regimen may be more effective, and that medication adherence was unknown.
HCQ dosing was 600mg/day for 1 week, therapeutic levels may not be reached for several days. There were no deaths or serious adverse events.
Viral load was already very high at baseline.
risk of hospitalization, 33.3% higher, RR 1.33, p = 1.00, treatment 4 of 152 (2.6%), control 3 of 152 (2.0%), HCQ+AZ vs. HCQ.
progression to pneumonia, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 152 (0.7%), control 3 of 152 (2.0%), NNT 76, HCQ+AZ vs. HCQ.
risk of symptomatic at day 21, 100% higher, RR 2.00, p = 0.50, treatment 6 of 152 (3.9%), control 3 of 152 (2.0%), HCQ+AZ vs. HCQ.
relative improvement in Ct, 4.2% worse, RR 1.04, p = 0.63, treatment 152, control 152, HCQ+AZ vs. HCQ, day 6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Omrani et al., 20 Nov 2020, Double Blind Randomized Controlled Trial, placebo-controlled, Qatar, peer-reviewed, 19 authors, study period 13 April, 2020 - 1 August, 2020, Q-PROTECT trial.
This PaperAzithromycinAll
{ 'indexed': {'date-parts': [[2024, 1, 25]], 'date-time': '2024-01-25T15:46:37Z', 'timestamp': 1706197597142}, 'reference-count': 33, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 12, 1]], 'date-time': '2020-12-01T00:00:00Z', 'timestamp': 1606780800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 11, 6]], 'date-time': '2020-11-06T00:00:00Z', 'timestamp': 1604620800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/100007833', 'name': 'Hamad Medical Corporation', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1016/j.eclinm.2020.100645', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 20]], 'date-time': '2020-11-20T22:24:37Z', 'timestamp': 1605911077000}, 'page': '100645', 'source': 'Crossref', 'is-referenced-by-count': 42, 'title': 'Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without ' 'azithromycin for virologic cure of non-severe Covid-19', 'prefix': '10.1016', 'volume': '29-30', 'author': [ {'given': 'Ali S.', 'family': 'Omrani', 'sequence': 'first', 'affiliation': []}, {'given': 'Sameer A.', 'family': 'Pathan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarah A.', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tim R.E.', 'family': 'Harris', 'sequence': 'additional', 'affiliation': []}, {'given': 'Peter V.', 'family': 'Coyle', 'sequence': 'additional', 'affiliation': []}, {'given': 'Caroline E.', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Isma', 'family': 'Qureshi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zain A.', 'family': 'Bhutta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Naema Al', 'family': 'Mawlawi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Reham Al', 'family': 'Kahlout', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ashraf', 'family': 'Elmalik', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aftab M.', 'family': 'Azad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joanne', 'family': 'Daghfal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mulham', 'family': 'Mustafa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrew', 'family': 'Jeremijenko', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hussam Al', 'family': 'Soub', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammed Abu', 'family': 'Khattab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Muna Al', 'family': 'Maslamani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stephen H.', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.eclinm.2020.100645_bib0001', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0002', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101663', 'article-title': 'Clinical and microbiological effect of a combination of ' 'hydroxychloroquine and azithromycin in 80 COVID-19 patients with at ' 'least a six-day follow up: a pilot observational study', 'volume': '34', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0003', 'author': 'Molina', 'year': '2020', 'journal-title': 'Med Mal Infect'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0004', 'unstructured': 'Ferner R.E., Aronson J.K... Hydroxychloroquine for Covid-19: what do the ' 'clinical trials tell us? 2020. ' 'https://www.cebm.net/covid-19/hydroxychloroquine-for-covid-19-what-do-the-clinical-trials-tell-us/ ' '(accessed 20 April 2020).'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0005', 'unstructured': 'Q-PROTECT Research Protocol. 2020. ' 'https://www.hamad.qa/EN/Hospitals-and-services/Communicable-Disease-Center/Research-and-Education/Pages/Q-Protect.aspx ' '(accessed 1 August 2020).'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0006', 'unstructured': 'Simpson T.F., Kovacs R.J., Stecker E.C.. Ventricular arrhythmia risk due ' 'to hydroxychloroquine-azithromycin treatment for Covid-19. 2020. ' 'https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 ' '(accessed 1 April 2020).'}, { 'issue': '12', 'key': '10.1016/j.eclinm.2020.100645_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '1177', 'DOI': '10.1056/NEJMc2001737', 'article-title': 'SARS-CoV-2 viral load in upper respiratory specimens of infected ' 'patients', 'volume': '382', 'author': 'Zou', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '120', 'DOI': '10.1016/j.jclinepi.2020.04.016', 'article-title': 'COVID-19 coronavirus research has overall low methodological quality ' 'thus far: case in point for chloroquine/hydroxychloroquine', 'volume': '123', 'author': 'Alexander', 'year': '2020', 'journal-title': 'J Clin Epidemiol'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0009', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for covid-19', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0010', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101738', 'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and ' 'azithromycin: a retrospective analysis of 1061 cases in Marseille, ' 'France', 'volume': '35', 'author': 'Million', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0011', 'article-title': 'Hydroxychloroquine for early treatment of adults with mild covid-19: a ' 'randomized-controlled trial', 'author': 'Mitja', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0012', 'doi-asserted-by': 'crossref', 'DOI': '10.7326/M20-4207', 'article-title': 'Hydroxychloroquine in nonhospitalized adults with early COVID-19: a ' 'randomized trial', 'author': 'Skipper', 'year': '2020', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0013', 'doi-asserted-by': 'crossref', 'first-page': 'm1849', 'DOI': '10.1136/bmj.m1849', 'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus ' 'disease 2019: open label, randomised controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ'}, { 'issue': '2', 'key': '10.1016/j.eclinm.2020.100645_bib0014', 'first-page': '215', 'article-title': 'A pilot study of hydroxychloroquine in treatment of patients with ' 'moderate COVID-19', 'volume': '49', 'author': 'Chen', 'year': '2020', 'journal-title': 'Zhejiang Da Xue Xue Bao Yi Xue Ban'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0015', 'article-title': 'Low dose of hydroxychloroquine reduces fatality of critically ill ' 'patients with COVID-19', 'author': 'Yu', 'year': '2020', 'journal-title': 'Sci China Life Sci'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0016', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with ' 'covid-19', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0017', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with ' 'in-hospital mortality in patients with COVID-19 in New York State', 'author': 'Rosenberg', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0018', 'doi-asserted-by': 'crossref', 'first-page': 'm1844', 'DOI': '10.1136/bmj.m1844', 'article-title': 'Clinical efficacy of hydroxychloroquine in patients with covid-19 ' 'pneumonia who require oxygen: observational comparative study using ' 'routine care data', 'volume': '369', 'author': 'Mahevas', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0019', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamacardio.2020.1782', 'article-title': 'Hydroxychloroquine, coronavirus disease 2019, and QT prolongation', 'author': 'Bonow', 'year': '2020', 'journal-title': 'JAMA Cardiol'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0020', 'article-title': 'Hydroxychloroquine or chloroquine with or without a macrolide for ' 'treatment of COVID-19: a multinational registry analysis', 'author': 'Mehra', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0021', 'unstructured': 'Horby P., Landray M.J... No clinical benefit from use of ' 'hydroxychloroquine in hospitalised patients with Covid-19. 2020. ' 'https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 ' '(accessed 1 July 2020).'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0022', 'unstructured': 'FDA cautions against use of hydroxychloroquine or chloroquine for ' 'COVID-19 outside of the hospital setting or a clinical trial due to risk ' 'of heart rhythm problems. 2020. ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or ' '(accessed 15 July 2020).'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0023', 'unstructured': 'WHO. "Solidarity" clinical trial for Covid-19 treatments. 2020. ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments ' '(accessed 15 July 2020).'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0024', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2019014', 'article-title': 'Hydroxychloroquine with or without azithromycin in mild-to-moderate ' 'covid-19', 'author': 'Cavalcanti', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '396', 'DOI': '10.1016/j.ijid.2020.06.099', 'article-title': 'Treatment with hydroxychloroquine, azithromycin, and combination in ' 'patients hospitalized with COVID-19', 'volume': '97', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0026', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101791', 'article-title': 'Outcomes of 3,737 COVID-19 patients treated with ' 'hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis', 'author': 'Lagier', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'issue': '6', 'key': '10.1016/j.eclinm.2020.100645_bib0027', 'doi-asserted-by': 'crossref', 'first-page': '585', 'DOI': '10.1056/NEJMe2020388', 'article-title': 'Hydroxychloroquine for the prevention of Covid-19 – searching for ' 'evidence', 'volume': '383', 'author': 'Cohen', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0028', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jinf.2020.06.034', 'article-title': 'Low transmission risk of 9 asymptomatic carriers tested positive for ' 'both SARS-CoV-2 nucleic acid and serum IgG', 'author': 'Chen', 'year': '2020', 'journal-title': 'J Infect'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0029', 'article-title': 'Temporal dynamics in viral shedding and transmissibility of COVID-19', 'author': 'He', 'year': '2020', 'journal-title': 'Nat Med'}, { 'issue': '4', 'key': '10.1016/j.eclinm.2020.100645_bib0030', 'doi-asserted-by': 'crossref', 'first-page': 'ofaa130', 'DOI': '10.1093/ofid/ofaa130', 'article-title': 'Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 ' '(COVID-19)', 'volume': '7', 'author': 'Pastick', 'year': '2020', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '15', 'key': '10.1016/j.eclinm.2020.100645_bib0031', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of Severe Acute Respiratory ' 'Syndrome Coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'issue': '3', 'key': '10.1016/j.eclinm.2020.100645_bib0032', 'doi-asserted-by': 'crossref', 'first-page': '287', 'DOI': '10.2174/1573403X10666140514103612', 'article-title': 'The measurement of the QT interval', 'volume': '10', 'author': 'Postema', 'year': '2014', 'journal-title': 'Curr Cardiol Rev'}, { 'key': '10.1016/j.eclinm.2020.100645_bib0033', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamacardio.2020.1787', 'article-title': 'Assessment of QT intervals in a case series of patients with ' 'coronavirus disease 2019 (COVID-19) infection treated with ' 'hydroxychloroquine alone or in combination with azithromycin in an ' 'intensive care unit', 'author': 'Bessiere', 'year': '2020', 'journal-title': 'JAMA Cardiol'}], 'container-title': 'EClinicalMedicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537020303898?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537020303898?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 5, 13]], 'date-time': '2021-05-13T12:00:34Z', 'timestamp': 1620907234000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2589537020303898'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12]]}, 'references-count': 33, 'alternative-id': ['S2589537020303898'], 'URL': 'http://dx.doi.org/10.1016/j.eclinm.2020.100645', 'relation': {}, 'ISSN': ['2589-5370'], 'subject': ['General Medicine'], 'container-title-short': 'EClinicalMedicine', 'published': {'date-parts': [[2020, 12]]}, 'article-number': '100645'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit